Latest Hotspot

Arvinas' two AR receptor PROTAC therapies show positive results in Phase 1/2 clinical trials

26 October 2023
3 min read

Recently, Arvinas Inc. announced positive efficacy and tolerance results of its PROTAC protein degrader targeting androgen receptor (AR), bavdegalutamide (ARV-110), and its second-generation AR-targeted PROTAC degrader ARV-766 in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in Phase 1/2 clinical trials at the European Society for Medical Oncology (ESMO). Based on this data, Arvinas plans to prioritize the initiation of Phase 3 clinical trials for ARV-766 in the treatment of mCRPC and is scheduled to have related discussions with regulatory bodies in the second quarter of 2024.

ARV-110 is a PROTAC drug developed by Arvinas for the treatment of prostate cancer. It demonstrated satisfactory safety and tolerance in Phase I clinical trials. ARV-110 is the first PROTAC to enter clinical trials. Its oral administration can effectively degrade wild-type AR and AR variants induced by antiandrogen treatment. In various prostate cancer cell lines, ARV-110 can degrade 95-98% of ARs. In drug-resistant models, ARV-110 can reduce tumor growth by 70-100%. Preliminary data from the Phase 1 clinical trials indicate that ARV-110 displays satisfactory safety and tolerance in patients.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

ARV-766, the second-generation oral AR degrader developed by Arvinas, has broader genotype coverage and better stereochemical stability than its predecessor ARV-110. All AR LBD mutations, especially AR L702H, increase in frequency over time. About 25% of tumors have these mutations after initial treatment with new hormone drugs (NHAs) such as enzalutamide or abiraterone.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Extended follow-up data from the Phase 1/2 clinical trials of ARV-110 showed radiographic progression-free survival (rPFS) of 11.1 months in the mCRPC patients cohort with AR T878X/H878Y mutations (AR 878/875; T878X=T878A or T878S) in the absence of AR L702H mutations. 54% of patients’ prostate-specific antigen (PSA) levels decreased by ≥50% (PSA50). In patients with any AR LBD mutation (excluding L702H mutation), the rPFS of ARV-110 was 8.2 months, with 36% of patients achieving PSA50. However, only 8% of patients with AR L702H mutations achieved PSA50 after treatment with ARV-110.

The most recent clinical trial results showed that ARV-766 decreased the PSA levels by ≥50% in 42% of patients with AR ligand-binding domain (LBD) mutations. 3 out of 5 patients with AR L702H mutations achieved PSA50. Among these 3 cases of AR L702H mutation, all of them also showed concurrent T878/H875 mutations. In 4 RECIST-evaluable patients with tumors with AR LBD mutations, two observed partial remission (1 confirmed partial remission, 1 unconfirmed partial remission). ARV-766 is currently also in the Phase 2 clinical research stage.

According to information disclosed by the synapse database, as of October 25, 2023, there are 247 in-developed drugs targeting AR, including 174 indications, 273 research institutions involved, 2068 related clinical trials, and as many as 181,693 patents. ARV-766 has shown signs of efficacy in late-stage cancer patients and has good tolerance. It is expected to break through the unmet medical needs of castration-resistance and castration-sensitive prostate cancer.

Mapping the Evolution of the Competitive Landscape of Mirvetuximab Soravtansine
Bio Sequence
3 min read
Mapping the Evolution of the Competitive Landscape of Mirvetuximab Soravtansine
26 October 2023
In mapping the evolutionary trajectory of the patenting landscape pertaining to Mirvetuximab Soravtansine, it is critical to analyze the strategic approach of the top 10 assignees. There is also a dynamic shift in the competition blueprint that is dictated by the progression of time.
Read →
Benzydamine Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Benzydamine Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
30 October 2023
This article summarized the latest R&D progress of Benzydamine Hydrochloride, the Mechanism of Action for Benzydamine Hydrochloride, and the drug target R&D trends for Benzydamine Hydrochloride.
Read →
 Unleashing the Power of Benazepril Hydrochloride: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Benazepril Hydrochloride: A Comprehensive Review on R&D Breakthroughs
30 October 2023
This article summarized the latest R&D progress of Benazepril Hydrochloride, the Mechanism of Action for Benazepril Hydrochloride, and the drug target R&D trends for Benazepril Hydrochloride.
Read →
A Comprehensive Review of Belantamab mafodotin's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Belantamab mafodotin's R&D Innovations and Drug Target Mechanism
30 October 2023
This article summarized the latest R&D progress of Belantamab mafodotin, the Mechanism of Action for Belantamab mafodotin, and the drug target R&D trends for Belantamab mafodotin.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.